Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem

J. D. Kark, J. Selhub, B. Adler, Jaime Gofin, J. H. Abramson, G. Friedman, I. H. Rosenberg

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

Background: Elevated plasma total homocysteine level has been associated with cardiovascular disease in many studies, mostly in Europe and North America. Data on persons from other areas and on associations with overall mortality are sparse. Objective: To determine the relation of plasma homocysteine level to all-cause and cause-specific mortality. Design: Prospective observational study with 9- to 11-year follow-up. Setting: A free-living, multiethnic Jewish population in western Jerusalem, Israel. Participants: 1788 residents of Jerusalem (808 men and 980 women) who were at least 50 years of age and were examined between 1985 and 1987 as part of the Kiryat Yovel Community Health Study. Measurements: Nonfasting plasma homocysteine level was determined in frozen stored samples. Deaths during follow-up were identified by linkage with the national population registry. Results: Plasma homocysteine levels exceeded 14 μmol/L in 28% of men and 20% of women. During the study period, 405 deaths occurred. In multivariate Cox models that controlled for possible confounders, a nonmonotonic increase in mortality hazard ratios was associated with ascending quintile of homocysteine level: 1.0, 1.4, 1.3, 1.5, and 2.0 (P < 0.001 for trend). The relation was similar for cardiovascular and noncardiovascular causes of death (excluding cancer). The association was weaker when deaths that occurred during the first 5 years of follow-up were excluded; corresponding hazard ratios for ascending quintile of homocysteine level were 1.0, 1.0, 1.2, 1.1, and 1.6 (P = 0.063 for trend). Age- and sex-adjusted percentages of deaths 'attributable' to elevated plasma homocysteine level (≥14 μmol/L) were 12.5% (95% CI, 6.7% to 18.8%) for all deaths, 16.0% (CI, 7.2% to 25.6%) for deaths during the first 5 years of follow-up, and 8.3% (CI, 1.5% to 16.1%) for later deaths. Conclusions: A mildly to moderately elevated nonfasting plasma homocysteine level is a substantial risk marker for death from all causes. The association seems to be stronger during the first 5 years of follow-up.

Original languageEnglish (US)
Pages (from-to)321-330
Number of pages10
JournalAnnals of internal medicine
Volume131
Issue number5
DOIs
StatePublished - Sep 7 1999

Fingerprint

Homocysteine
Mortality
Cause of Death
Israel
North America
Proportional Hazards Models
Population
Observational Studies
Registries
Cardiovascular Diseases
Prospective Studies
Health

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem. / Kark, J. D.; Selhub, J.; Adler, B.; Gofin, Jaime; Abramson, J. H.; Friedman, G.; Rosenberg, I. H.

In: Annals of internal medicine, Vol. 131, No. 5, 07.09.1999, p. 321-330.

Research output: Contribution to journalArticle

Kark, J. D. ; Selhub, J. ; Adler, B. ; Gofin, Jaime ; Abramson, J. H. ; Friedman, G. ; Rosenberg, I. H. / Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem. In: Annals of internal medicine. 1999 ; Vol. 131, No. 5. pp. 321-330.
@article{8e7e1b17f6244e30a98494420ad9c1c7,
title = "Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem",
abstract = "Background: Elevated plasma total homocysteine level has been associated with cardiovascular disease in many studies, mostly in Europe and North America. Data on persons from other areas and on associations with overall mortality are sparse. Objective: To determine the relation of plasma homocysteine level to all-cause and cause-specific mortality. Design: Prospective observational study with 9- to 11-year follow-up. Setting: A free-living, multiethnic Jewish population in western Jerusalem, Israel. Participants: 1788 residents of Jerusalem (808 men and 980 women) who were at least 50 years of age and were examined between 1985 and 1987 as part of the Kiryat Yovel Community Health Study. Measurements: Nonfasting plasma homocysteine level was determined in frozen stored samples. Deaths during follow-up were identified by linkage with the national population registry. Results: Plasma homocysteine levels exceeded 14 μmol/L in 28{\%} of men and 20{\%} of women. During the study period, 405 deaths occurred. In multivariate Cox models that controlled for possible confounders, a nonmonotonic increase in mortality hazard ratios was associated with ascending quintile of homocysteine level: 1.0, 1.4, 1.3, 1.5, and 2.0 (P < 0.001 for trend). The relation was similar for cardiovascular and noncardiovascular causes of death (excluding cancer). The association was weaker when deaths that occurred during the first 5 years of follow-up were excluded; corresponding hazard ratios for ascending quintile of homocysteine level were 1.0, 1.0, 1.2, 1.1, and 1.6 (P = 0.063 for trend). Age- and sex-adjusted percentages of deaths 'attributable' to elevated plasma homocysteine level (≥14 μmol/L) were 12.5{\%} (95{\%} CI, 6.7{\%} to 18.8{\%}) for all deaths, 16.0{\%} (CI, 7.2{\%} to 25.6{\%}) for deaths during the first 5 years of follow-up, and 8.3{\%} (CI, 1.5{\%} to 16.1{\%}) for later deaths. Conclusions: A mildly to moderately elevated nonfasting plasma homocysteine level is a substantial risk marker for death from all causes. The association seems to be stronger during the first 5 years of follow-up.",
author = "Kark, {J. D.} and J. Selhub and B. Adler and Jaime Gofin and Abramson, {J. H.} and G. Friedman and Rosenberg, {I. H.}",
year = "1999",
month = "9",
day = "7",
doi = "10.7326/0003-4819-131-5-199909070-00002",
language = "English (US)",
volume = "131",
pages = "321--330",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "5",

}

TY - JOUR

T1 - Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem

AU - Kark, J. D.

AU - Selhub, J.

AU - Adler, B.

AU - Gofin, Jaime

AU - Abramson, J. H.

AU - Friedman, G.

AU - Rosenberg, I. H.

PY - 1999/9/7

Y1 - 1999/9/7

N2 - Background: Elevated plasma total homocysteine level has been associated with cardiovascular disease in many studies, mostly in Europe and North America. Data on persons from other areas and on associations with overall mortality are sparse. Objective: To determine the relation of plasma homocysteine level to all-cause and cause-specific mortality. Design: Prospective observational study with 9- to 11-year follow-up. Setting: A free-living, multiethnic Jewish population in western Jerusalem, Israel. Participants: 1788 residents of Jerusalem (808 men and 980 women) who were at least 50 years of age and were examined between 1985 and 1987 as part of the Kiryat Yovel Community Health Study. Measurements: Nonfasting plasma homocysteine level was determined in frozen stored samples. Deaths during follow-up were identified by linkage with the national population registry. Results: Plasma homocysteine levels exceeded 14 μmol/L in 28% of men and 20% of women. During the study period, 405 deaths occurred. In multivariate Cox models that controlled for possible confounders, a nonmonotonic increase in mortality hazard ratios was associated with ascending quintile of homocysteine level: 1.0, 1.4, 1.3, 1.5, and 2.0 (P < 0.001 for trend). The relation was similar for cardiovascular and noncardiovascular causes of death (excluding cancer). The association was weaker when deaths that occurred during the first 5 years of follow-up were excluded; corresponding hazard ratios for ascending quintile of homocysteine level were 1.0, 1.0, 1.2, 1.1, and 1.6 (P = 0.063 for trend). Age- and sex-adjusted percentages of deaths 'attributable' to elevated plasma homocysteine level (≥14 μmol/L) were 12.5% (95% CI, 6.7% to 18.8%) for all deaths, 16.0% (CI, 7.2% to 25.6%) for deaths during the first 5 years of follow-up, and 8.3% (CI, 1.5% to 16.1%) for later deaths. Conclusions: A mildly to moderately elevated nonfasting plasma homocysteine level is a substantial risk marker for death from all causes. The association seems to be stronger during the first 5 years of follow-up.

AB - Background: Elevated plasma total homocysteine level has been associated with cardiovascular disease in many studies, mostly in Europe and North America. Data on persons from other areas and on associations with overall mortality are sparse. Objective: To determine the relation of plasma homocysteine level to all-cause and cause-specific mortality. Design: Prospective observational study with 9- to 11-year follow-up. Setting: A free-living, multiethnic Jewish population in western Jerusalem, Israel. Participants: 1788 residents of Jerusalem (808 men and 980 women) who were at least 50 years of age and were examined between 1985 and 1987 as part of the Kiryat Yovel Community Health Study. Measurements: Nonfasting plasma homocysteine level was determined in frozen stored samples. Deaths during follow-up were identified by linkage with the national population registry. Results: Plasma homocysteine levels exceeded 14 μmol/L in 28% of men and 20% of women. During the study period, 405 deaths occurred. In multivariate Cox models that controlled for possible confounders, a nonmonotonic increase in mortality hazard ratios was associated with ascending quintile of homocysteine level: 1.0, 1.4, 1.3, 1.5, and 2.0 (P < 0.001 for trend). The relation was similar for cardiovascular and noncardiovascular causes of death (excluding cancer). The association was weaker when deaths that occurred during the first 5 years of follow-up were excluded; corresponding hazard ratios for ascending quintile of homocysteine level were 1.0, 1.0, 1.2, 1.1, and 1.6 (P = 0.063 for trend). Age- and sex-adjusted percentages of deaths 'attributable' to elevated plasma homocysteine level (≥14 μmol/L) were 12.5% (95% CI, 6.7% to 18.8%) for all deaths, 16.0% (CI, 7.2% to 25.6%) for deaths during the first 5 years of follow-up, and 8.3% (CI, 1.5% to 16.1%) for later deaths. Conclusions: A mildly to moderately elevated nonfasting plasma homocysteine level is a substantial risk marker for death from all causes. The association seems to be stronger during the first 5 years of follow-up.

UR - http://www.scopus.com/inward/record.url?scp=0033533458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033533458&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-131-5-199909070-00002

DO - 10.7326/0003-4819-131-5-199909070-00002

M3 - Article

VL - 131

SP - 321

EP - 330

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 5

ER -